Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance to Refine Clinical Management Strategies

Learn how experts leverage BTK inhibitors for optimal management of patients with MCL, CLL, and other B-cell malignancies in this CME-certified, on-demand Webcast of a dynamic CCO symposium at ASH 2019.
Ian W. Flinn, MD, PhD
Program Director
Jan A. Burger, MD, PhD
Alexey Danilov, MD
John Pagel Headshot
John Pagel, MD, PhD
Released: February 4, 2020 Expiration: No longer available for credit

Related Content

Experts highlight key studies being presented at the 2022 ASH Annual Meeting in this commentary from Clinical Care Options (CCO)

Catherine M. Broome, MD John M. Burke, MD Corey Cutler, MD, MPH, FRCPC person default David Dingli, MD, PhD Amir T. Fathi, MD Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Marshall Mazepa, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Allison Wheeler, MD, MSCI Amer Zeidan, MBBS, MPH Released: December 7, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Adolfo de la Fuente Burguera, MD
Program Director
Claudio Cerchione, MD, PhD Naval G. Daver, MD person default Pau Montesinos, MD, PhD Eytan M. Stein, MD
Released: December 1, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director
Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE person default Giovanni Martinelli, MD
Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)

Released: November 29, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings